) shares rose 1.8% in early New York trading on Wednesday after the company reported third-quarter results that topped analyst expectations.
In terms of specific product revenues, Biogen reported $1.16 billion in revenue for multiple sclerosis, in line with the estimate. Revenue for Spinraza reached $448.2 million, exceeding the estimate of $434.9 million.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MarketWatch - 🏆 3. / 97 Read more »